Comparing Effects of Beetroot Juice and Mediterranean Diet on Liver Enzymes and Sonography in Patients With NAFLD
NCT05909631 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180
Last updated 2023-06-18
Summary
The goal of this clinical trial study is to investigate comparing Effects of Beetroot juice and Mediterranean diet on Liver Enzymes and Sonographic appearance in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
The main question\[s\] it aims to answer are:
1. Beetroot juice has role in reduce Liver Enzymes
2. Mediterranean diet has role in reduce Liver Enzymes
Conditions
- NAFLD, Non-alcoholic Fatty Liver Disease
Interventions
- OTHER
-
Beetroot juice
250 ml of concentrated beetroot juice, were given to participants in the BJ groups .This was carried out in the morning, 30 minutes before breakfast, and on an empty stomach.
- OTHER
-
placebo
250 ml of a placebo
- OTHER
-
Mediterranean diet alone (MeD)
Mediterranean diet alone (MeD)
- COMBINATION_PRODUCT
-
Mediterranean diet with beet juice (BJ+MeD)
Mediterranean diet with beet juice (BJ+MeD).
Sponsors & Collaborators
-
Sulaimany Polytechnic university
lead OTHER
Principal Investigators
-
Hawal Lateef, Msc · Nursing department, sulaimany polytechni university, kurdistan, iraq
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Max Age
- 73 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-01-10
- Primary Completion
- 2023-02-20
- Completion
- 2023-04-11
- FDA Drug
- Yes
Countries
- Iraq
Study Locations
More Related Trials
-
Betaine in Patients With Nonalcoholic Steatohepatitis
NCT00586911 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
NCT02369536 ·Status: COMPLETED ·Phase: NA
-
The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
NCT02030977 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
NCT06739486 ·Status: NOT_YET_RECRUITING
-
A Hepatitis B With Hepatic Steatosis Study
NCT02392598 ·Status: UNKNOWN
-
Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials
NCT03611101 ·Status: COMPLETED
-
Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients
NCT06503068 ·Status: RECRUITING
-
A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.
NCT05857644 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment
NCT04308980 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Study of Metabolic Dysfunction-Associated Steatotic Liver Disease Among Sohag University Employees
NCT06536933 ·Status: NOT_YET_RECRUITING
-
Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
NCT05946330 ·Status: UNKNOWN ·Phase: NA
-
Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment
NCT01987310 ·Status: WITHDRAWN ·Phase: NA
-
Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
NCT05768334 ·Status: COMPLETED ·Phase: PHASE3
-
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
NCT06117137 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
NCT06773221 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Enhanced Liver Function in Non-alcoholic Obese Fatty Liver Patients by Low Level Laser Therapy
NCT04452409 ·Status: COMPLETED ·Phase: NA
-
A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
NCT05917938 ·Status: COMPLETED ·Phase: PHASE1
-
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
NCT05966025 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
NCT03061721 ·Status: COMPLETED ·Phase: PHASE2
-
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
NCT00529204 ·Status: TERMINATED ·Phase: PHASE2
-
6-week Safety and PD Study in Adults With NAFLD
NCT03256526 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
NCT02303314 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
NCT02605616 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis
NCT01650181 ·Status: COMPLETED ·Phase: PHASE4
-
Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
NCT00375349 ·Status: WITHDRAWN ·Phase: NA